Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKN-01 +/- Docetaxel in Advanced Prostate Cancer
NCT03837353Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Apr 2019
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sirexatamab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by NYU Langone Health. Started Apr 2019; status: terminated.
02
Drugs
sirexatamab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03837353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837353.